[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2026-09-26-26":3},{"date":4,"filings":5,"has_more":122,"limit":123,"page":124,"total_count":125},"2026-09-26",[6,14,21,25,32,36,41,45,52,59,63,70,74,82,86,93,98,102,107,111,118],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"UMIYA BUILDCON LIMITED","2026-09-26T08:05:26.561000","NSE","Trading Window Closing Ahead of Quarterly Results","6ab72fa5dc9a8790cc747f73","UMIYA-MRO","*   The company has announced the closure of its trading window for designated persons starting from **October 01, 2026**.\n*   This is in preparation for the announcement of the unaudited financial results for the quarter ending September 30, 2026.\n*   The trading window will reopen 48 hours after the financial results are made public.\n*   The date of the Board Meeting to approve these results will be announced in due course.",{"company_name":15,"filing_date":16,"filing_source":9,"headline":17,"id":18,"stock_code":19,"summary_text":20},"Cholamandalam Investment and Finance Company Limited","2026-09-26T08:00:27.224000","Allots 54,302 Equity Shares Under ESOP","6ab72e8d58e45d3ba429bc24","CHOLAFIN","*   The company has allotted 54,302 new equity shares to employees under its Employee Stock Option Scheme (ESOP).\n*   The shares have a face value of Rs. 2\u002F- each and were approved by the Nomination and Remuneration Committee.\n*   This allotment will result in a minor increase in the company's paid-up equity share capital.\n*   The company will apply to list the newly allotted shares on the NSE and BSE.",{"company_name":15,"filing_date":16,"filing_source":9,"headline":22,"id":23,"stock_code":19,"summary_text":24},"Issues New Equity Shares Under Employee Stock Option Scheme","6ab72ea9dc9a8790cc747f72","*   The company has allotted **54,302 new equity shares** with a face value of Rs. 2 each.\n*   This allotment was made to eligible employees who exercised their options under the company's Employee Stock Option Scheme (ESOS).\n*   The allotment was approved by the Nomination and Remuneration Committee.\n*   The company will now apply to list these new shares on the NSE and BSE stock exchanges.",{"company_name":26,"filing_date":27,"filing_source":9,"headline":28,"id":29,"stock_code":30,"summary_text":31},"Reliance Power Limited","2026-09-26T00:30:26.763000","Trading Window to Close for Q2 FY27 Results","6ab6c4e858e45d3ba429bc20","RPOWER","• The trading window for \"Designated Persons\" will be closed starting Thursday, October 01, 2026.\n• This is in preparation for the announcement of financial results for the quarter and half-year ending September 30, 2026.\n• The window will reopen 48 hours after the financial results are made public.\n• This is a routine compliance measure and does not impact the trading rights of general shareholders.",{"company_name":26,"filing_date":27,"filing_source":9,"headline":33,"id":34,"stock_code":30,"summary_text":35},"Trading Window Closure Ahead of Financial Results","6ab6c504bc0109c085e0554b","*   The trading window for the company's securities will be closed for all Designated Persons starting Thursday, October 1, 2026.\n*   This closure is a mandatory compliance measure ahead of the announcement of the unaudited financial results for the quarter and half-year ending September 30, 2026.\n*   The trading window will reopen 48 hours after the financial results are publicly declared.\n*   This is a standard procedural filing and does not contain any financial results.",{"company_name":26,"filing_date":37,"filing_source":9,"headline":38,"id":39,"stock_code":30,"summary_text":40},"2026-09-26T00:30:26.761000","Non-Executive Director Steps Down","6ab6c4efc8f6cdbfdae05772","*   **Change:** Mr. Sachin Mohapatra has resigned as a Non-Executive Non-Independent Director.\n*   **Reason:** The filing cites \"Personal family reasons\" for the resignation.\n*   **Effective Date:** The resignation is effective September 25, 2026.\n*   **Confirmation:** The company has confirmed there are no other material reasons for his departure.",{"company_name":26,"filing_date":37,"filing_source":9,"headline":42,"id":43,"stock_code":30,"summary_text":44},"Director Sachin Mohapatra Resigns from Board","6ab6c50503dafff8b629ba40","*   Mr. Sachin Mohapatra has resigned from his position as a Non-Executive Non-Independent Director.\n*   The resignation is effective from 25 September 2026.\n*   The stated reason for his departure is \"Personal family reasons\".\n*   The company has confirmed that there are no other material reasons for the resignation.",{"company_name":46,"filing_date":47,"filing_source":9,"headline":48,"id":49,"stock_code":50,"summary_text":51},"Sanofi India Limited","2026-09-26T00:30:26.704000","Sanofi India Receives ₹23.74 Crore Tax Notice","6ab6c4e573074a3af61b1fdf","SANOFI","*   The company has received a Show Cause Notice from the Commercial Tax Officer in Bengaluru for an alleged excess claim of Input Tax Credit (ITC) for FY 2022-23.\n*   The notice involves an alleged tax demand of ₹14.43 crore and interest of ₹9.31 crore, totaling approximately ₹23.74 crore.\n*   Sanofi India is currently examining the notice with its tax advisors and intends to submit a reply within the prescribed time.\n*   The company has stated that it does not expect any adverse impact on its financials, operations, or other activities from this notice.",{"company_name":53,"filing_date":54,"filing_source":9,"headline":55,"id":56,"stock_code":57,"summary_text":58},"Aditya Infotech Limited","2026-09-26T00:30:26.663000","Completes Major Capital Raise via QIP, Issues 11.83 Crore New Shares","6ab6c4f1dc9a8790cc747f71","CPPLUS","*   **Action:** Allotted 11,83,00,435 new equity shares to institutional investors via a Qualified Institutional Placement (QIP) on September 25, 2026.\n*   **Impact on Capital:** The company's paid-up share capital has increased significantly, from 43,26,507 to 1,22,626,942 shares.\n*   **Shareholder Dilution:** This action results in substantial equity dilution for pre-QIP shareholders, as the new shares constitute ~96.47% of the post-issue capital.\n*   **Next Steps:** Investors should monitor future disclosures on how the company plans to use the newly raised capital.",{"company_name":53,"filing_date":54,"filing_source":9,"headline":60,"id":61,"stock_code":57,"summary_text":62},"Announces Allotment of 118.3 Million Shares via QIP","6ab6c50d1a46555968747be5","• Allotted 118,300,435 new equity shares to Qualified Institutional Buyers (QIBs) through a Qualified Institutional Placement (QIP) on September 25, 2026.\n• The company's paid-up equity share capital has increased from 4,326,507 to 122,626,942 shares post-allotment.\n• This issuance results in significant equity dilution for existing shareholders, with the total number of shares increasing by approximately 96.47%.",{"company_name":64,"filing_date":65,"filing_source":9,"headline":66,"id":67,"stock_code":68,"summary_text":69},"RPG Life Sciences Limited","2026-09-26T00:15:27.014000","Announces Internal Restructuring via Subsidiary Merger","6ab6c17a73074a3af61b1fde","RPGLIFE","• The Board has approved a scheme to merge two subsidiaries: Actis Generics Private Limited will be amalgamated with RPG Active Pharma Limited.\n• This is an internal restructuring aimed at streamlining the corporate structure, improving operational efficiency, and reducing costs.\n• Since the transferor (Actis Generics) is a wholly-owned subsidiary of the transferee (RPG Active Pharma), no new shares will be issued as consideration.\n• The amalgamation will have **no impact** on the shareholding pattern of the parent company, RPG Life Sciences Limited.\n• The scheme is subject to necessary approvals, including from the National Company Law Tribunal (NCLT).",{"company_name":64,"filing_date":65,"filing_source":9,"headline":71,"id":72,"stock_code":68,"summary_text":73},"Strategic Merger of Subsidiaries for Efficiency","6ab6c195bc0109c085e0554a","*   The company has announced a proposed Scheme of Amalgamation between two of its subsidiary companies to streamline its Active Pharmaceutical Ingredient (API) business.\n*   **Actis Generics Private Limited** (Transferor Company) will be merged into **RPG Active Pharma Limited** (Transferee Company).\n*   The key objective is to simplify the corporate structure, improve operational efficiency, achieve cost savings, and create a stronger consolidated entity.\n*   The filing confirms there will be **no change** in the shareholding pattern of the listed company, RPG Life Sciences Limited, as a result of this amalgamation.\n*   The scheme is subject to approvals from the National Company Law Tribunal (NCLT), shareholders, and other regulatory authorities.",{"company_name":75,"filing_date":76,"filing_source":77,"headline":78,"id":79,"stock_code":80,"summary_text":81},"Sharika Enterprises Ltd","2026-09-26T00:15:26.628000","BSE","Raises ₹18.48 Crore via Preferential Allotment of Shares & Warrants","6ab6c183c8f6cdbfdae05771","540786","*   The company's board has approved the allotment of equity shares and convertible warrants, raising immediate funds of **₹18.48 crore**.\n*   **Equity Shares:** Allotted **1.21 crore shares** at an issue price of **₹14.33 per share**, aggregating to **₹17.47 crore**. These were allotted to 46 non-promoter entities.\n*   **Warrants:** Allotted **28.12 lakh warrants** (convertible to shares) at **₹14.33 per warrant** to both promoter and non-promoter groups. The company has received **₹1.01 crore** as the 25% upfront payment.\n*   **Conversion:** Warrant holders can convert them into equity shares within **18 months** by paying the remaining 75% of the price, which could bring in an additional **₹3.02 crore**.",{"company_name":75,"filing_date":76,"filing_source":77,"headline":83,"id":84,"stock_code":80,"summary_text":85},"Raises Capital via Preferential Allotment of Shares & Warrants","6ab6c19458e45d3ba429bc1f","*   The Board has approved the preferential allotment of 1,21,92,125 equity shares to non-promoters, raising a total of **₹17.47 Crores**.\n*   Additionally, 28,12,315 convertible warrants have been allotted to both promoter and non-promoter entities.\n*   The company received an upfront payment of **₹1.00 Crore** for the warrants, with a potential for an additional ₹3.02 Crores upon conversion within the next 18 months.\n*   The issue price for both shares and warrants was fixed at **₹14.33** per security.\n*   This action increases the company's paid-up capital and results in immediate dilution for existing shareholders, with further dilution possible upon warrant conversion.",{"company_name":87,"filing_date":88,"filing_source":9,"headline":89,"id":90,"stock_code":91,"summary_text":92},"Virtual Galaxy Infotech Limited","2026-09-26T00:10:34.016000","AGM Results: All Resolutions Passed, Including Dividend & IPO Fund Use Change","6ab6c05773074a3af61b1fdd","VGINFOTECH","*   The company announced the results of its 29th Annual General Meeting (AGM) held on September 24, 2026. All 7 proposed resolutions were passed with the requisite majority.\n*   A final dividend of **Re. 1\u002F- per equity share** for the financial year 2025-26 was confirmed.\n*   Shareholders approved a **Special Resolution to vary the use of funds** raised from the company's Initial Public Offer (IPO), indicating a strategic shift.\n*   Key board changes were approved, including the re-appointment of Mr. Avinash Narayanrao Shende and the regularization of Mr. Sunil Kulkarni as a Professional Non-Executive Director.\n*   Approval was granted for material related party transactions with Finverse Private Limited and Paynext Private Limited.",{"company_name":75,"filing_date":94,"filing_source":77,"headline":95,"id":96,"stock_code":80,"summary_text":97},"2026-09-26T00:10:26.847000","Board Approves Capital Raise via Preferential Allotment of Shares & Warrants","6ab6c05758e45d3ba429bc1e","• The Board has approved the preferential allotment of 1,21,92,125 equity shares and 28,12,315 convertible warrants.\n• A total of ₹17.47 crore will be raised from the equity share issue at a price of ₹14.33 per share.\n• The warrants, also priced at ₹14.33, will bring in an upfront amount of ₹1.00 crore, with a total potential infusion of ₹4.03 crore upon full conversion.\n• The total potential capital to be raised from both instruments is ₹21.50 crore.\n• Equity shares were allotted to 46 non-promoters, while warrants were allotted to 2 promoters and 4 non-promoters.\n• Post-allotment, the company's paid-up equity share capital will increase to 5,54,92,125 shares.",{"company_name":75,"filing_date":94,"filing_source":77,"headline":99,"id":100,"stock_code":80,"summary_text":101},"Board Approves Preferential Allotment of Shares & Warrants","6ab6c065853f8aacfe1b1c89","*   The Board has allotted 1,21,92,125 equity shares to non-promoters at an issue price of ₹14.33 per share, raising a total of **₹17.47 crore**.\n*   Additionally, 28,12,315 convertible warrants were allotted to promoter and non-promoter entities, raising an upfront amount of **₹1.00 crore**.\n*   The total immediate capital infusion for the company stands at **₹18.47 crore**, strengthening its financial position.\n*   Post-allotment, the issued equity share capital has increased to 5,54,92,125 shares, resulting in dilution for existing shareholders.",{"company_name":87,"filing_date":103,"filing_source":9,"headline":104,"id":105,"stock_code":91,"summary_text":106},"2026-09-26T00:05:32.908000","AGM Update: Final Dividend of Re. 1 Confirmed & IPO Strategy Shift Approved","6ab6bf4458e45d3ba429bc1d","*   **Final Dividend:** The interim dividend of **Re. 1\u002F- per equity share** for FY 2025-26 has been confirmed as the final dividend.\n*   **Strategic Shift:** A Special Resolution was passed to approve a **variation in the objects of the company's Initial Public Offer (IPO)**.\n*   **Board Updates:** **Mr. Avinash Narayanrao Shende** was re-appointed as a Director, and **Mr. Sunil Kulkarni** was regularized as a Professional Non-Executive Director.\n*   **Related Party Transactions:** Material RPTs with **Finverse Private Limited** and **Paynext Private Limited** were approved by shareholders.\n*   **Key Approvals:** All resolutions proposed at the 29th AGM, including the adoption of the Audited Standalone Financials for FY26, were passed with the requisite majority.",{"company_name":87,"filing_date":103,"filing_source":9,"headline":108,"id":109,"stock_code":91,"summary_text":110},"AGM Update: Dividend Confirmed & IPO Fund Use Changed","6ab6bf5673074a3af61b1fdc","*   **Dividend Finalized:** The interim dividend of **Re. 1\u002F- per share** was confirmed as the final dividend for FY 2025-26.\n*   **Strategic Shift:** Shareholders approved a **variation in the use of funds raised from the IPO**, signaling a change in the company's capital deployment strategy.\n*   **Board Changes:** Mr. Avinash Narayanrao Shende was re-appointed as a Director, and Mr. Sunil Kulkarni was regularized as a Professional Non-Executive Director.\n*   **All Resolutions Passed:** All 7 resolutions at the AGM were approved with the requisite majority, including material related party transactions and the adoption of financial statements.",{"company_name":112,"filing_date":113,"filing_source":9,"headline":114,"id":115,"stock_code":116,"summary_text":117},"Wheels India Limited","2026-09-26T00:05:27.538000","Successfully Raises ~₹250 Crore via QIP","6ab6bf35dc9a8790cc747f70","WHEELS","*   The company has raised **₹249.99 Crore** by completing a Qualified Institutions Placement (QIP).\n*   A total of **11,97,318 equity shares** were allotted at an issue price of **₹2088.00 per share**.\n*   Major allottees include Aditya Birla Sun Life Mutual Fund, SBI Balanced Hybrid Fund, and Ashoka India Equity Investment Trust PLC.\n*   Following the allotment, the company's paid-up equity share capital has increased to **₹26.86 Crore** from ₹25.66 Crore.",{"company_name":112,"filing_date":113,"filing_source":9,"headline":119,"id":120,"stock_code":116,"summary_text":121},"Successfully Raises ₹250 Crore via QIP","6ab6bf3c03dafff8b629ba3d","*   Successfully completed a Qualified Institutions Placement (QIP), raising approximately **₹250 Crores**.\n*   Allotted **11,97,318 equity shares** to Qualified Institutional Buyers (QIBs) at an issue price of **₹2,088.00 per share**.\n*   The company's paid-up equity share capital has increased from **₹25.67 Crores to ₹26.86 Crores** post-allotment.\n*   Major allottees include Aditya Birla Sun Life Mutual Fund, SBI Balanced Hybrid Fund, and Ashoka India Equity Investment Trust PLC.",false,100,26,2521]